While the C8A8 antibody combined with IL-7-CAR-T cell therapy has shown promising anti-tumor activity in NSCLC treatment, further optimization is needed to improve therapeutic efficacy. This evidence concerns the gene IL7 and non-small cell lung carcinoma.